The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis
Abstract
Methylprednisolone plays an important role in the current treatment of multiple sclerosis (MS), particularly in the acute phase of relapse. It acts in various ways to decrease the inflammatory cycle including: dampening the inflammatory cytokine cascade, inhibiting the activation of T cells, decreasing the extravasation of immune cells into the central nervous system, facilitating the apoptosis of activated immune cells, and indirectly decreasing the cytotoxic effects of nitric oxide and tumor necrosis factor alpha. This paper reviews the most recent observations on these mechanisms both to understand the disease mechanism and its treatment. As more becomes known about these mechanisms, it may become possible to design treatment regimes that are more specific towards both the individual and the disease state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD95–CD95L: can the brain learn from the immune system?
Becher, B., Owens, T., Antel, J. P., & Barker, P. A. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01180-6 · Cited by 63
Cited by
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
CTLA-4: From mechanism to autoimmune therapy
Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106221 · Cited by 297
Natalizumab for Multiple Sclerosis
Ransohoff, R. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmct071462 · Cited by 253
Molecular and cellular immune mediators of neuroprotection
Turrin, N. P., & Rivest, S. (2006) · Molecular Neurobiology · doi:10.1385/mn:34:3:221 · Cited by 85
Review: Brain—immune communication psychoneuroimmunology of multiple sclerosis
Kern, S., & Ziemssen, T. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458507079657 · Cited by 45
Metadata
- Authors
- Sloka, J. S., & Stefanelli, M.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2005-08
- Volume
- 11
- Issue
- 4
- Pages
- 425-432
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W1988098374
- Cited by
- 195
- References
- 1
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. https://app.cochat.ai/papers/10.1191/1352458505ms1190oa
- The paper
- Sloka, J. S., & Stefanelli, M. (2005). The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Multiple Sclerosis Journal. https://doi.org/10.1191/1352458505ms1190oa
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.